WO1994005332A3 - Glycolation de macromolecules glycosylees - Google Patents

Glycolation de macromolecules glycosylees Download PDF

Info

Publication number
WO1994005332A3
WO1994005332A3 PCT/US1993/008196 US9308196W WO9405332A3 WO 1994005332 A3 WO1994005332 A3 WO 1994005332A3 US 9308196 W US9308196 W US 9308196W WO 9405332 A3 WO9405332 A3 WO 9405332A3
Authority
WO
WIPO (PCT)
Prior art keywords
macromolecule
macromolecules
polyalkylene glycol
glycosylated
diamino compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/008196
Other languages
English (en)
Other versions
WO1994005332A2 (fr
Inventor
Timkulu Thabiso M
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlex Laboratories Inc
Original Assignee
Berlex Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories Inc filed Critical Berlex Laboratories Inc
Priority to AU50981/93A priority Critical patent/AU5098193A/en
Publication of WO1994005332A2 publication Critical patent/WO1994005332A2/fr
Publication of WO1994005332A3 publication Critical patent/WO1994005332A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé de couplage de glycols à des macromolécules par glycosylations sur ces dernières et non par des groupes amino ou carboxyle sur le squelette de celles-ci. On produit ainsi des macromolécules à réponse immunogène réduite et à activité maintenue. Ledit procédé de glycosylation d'une macromolécule glycosylée consiste à activer un glycol de polyalkylène; à faire réagir le glycol de polyalkylène activé avec un composé diamino, le glycol de polyalkylène activé étant couplé au composé diamino par un de ses groupes amino; à oxyder la macromolécule afin d'activer au moins un groupe glycosyl qu'elle contient; et à faire réagir le glycol de polyalkylène couplé au composé diamino avec le groupe glycosyl oxydé dans la macromolécule. On obtient ainsi une macromolécule glycosylée glycolée dans laquelle le glycol est lié à la macromolécule par ses glycosylations.
PCT/US1993/008196 1992-09-01 1993-09-01 Glycolation de macromolecules glycosylees Ceased WO1994005332A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50981/93A AU5098193A (en) 1992-09-01 1993-09-01 Glycolation of glycosylated macromolecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93777992A 1992-09-01 1992-09-01
US07/937,779 1992-09-01

Publications (2)

Publication Number Publication Date
WO1994005332A2 WO1994005332A2 (fr) 1994-03-17
WO1994005332A3 true WO1994005332A3 (fr) 1994-04-14

Family

ID=25470393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008196 Ceased WO1994005332A2 (fr) 1992-09-01 1993-09-01 Glycolation de macromolecules glycosylees

Country Status (2)

Country Link
AU (1) AU5098193A (fr)
WO (1) WO1994005332A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU721129B2 (en) * 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
ATE342729T1 (de) 1997-01-15 2006-11-15 Phoenix Pharmacologics Inc Modifizierter tumor-nekrosefaktor
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
BR0314227A (pt) * 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
WO2004046309A2 (fr) 2002-11-18 2004-06-03 Phoenix Pharmacologics, Inc. Methodes d'inhibition d'une replication virale in vivo
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
EP1613261A4 (fr) 2003-04-09 2011-01-26 Novo Nordisk As Formation intracellulaire de conjugues de peptides
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
EP1694347B1 (fr) 2003-11-24 2013-11-20 BioGeneriX AG Erythropoiétine glycopegylée
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド ＧｌｙｃｏＰＥＧ化卵胞刺激ホルモン
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
KR20070008645A (ko) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (fr) 2004-09-10 2006-03-23 Neose Technologies, Inc. Interferon alpha glycopegyle
WO2006050247A2 (fr) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
EP2975135A1 (fr) 2005-05-25 2016-01-20 Novo Nordisk A/S Facteur IX glycopégylé
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
WO2009140373A2 (fr) 2008-05-13 2009-11-19 Advanced Liquid Logic, Inc. Procédés, systèmes et dispositifs associés à un positionneur de gouttelettes
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2690611C (fr) 2007-06-12 2015-12-08 Novo Nordisk A/S Procede ameliore pour la production de sucres de nucleotide
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP3093029A1 (fr) 2009-07-27 2016-11-16 Baxalta GmbH Conjugués de protéines de coagulation sanguine
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006546A1 (fr) * 1988-01-20 1989-07-27 Cetus Corporation Conjugaison d'un polymere avec la proteine csf-1
EP0442724A2 (fr) * 1990-02-13 1991-08-21 Kirin-Amgen, Inc. IL-6 humaine modifiée
WO1993012220A1 (fr) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. ANTICORPS DE RECOMBINAISON ET CHIMERIQUES CONTRE c-erbB-2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006546A1 (fr) * 1988-01-20 1989-07-27 Cetus Corporation Conjugaison d'un polymere avec la proteine csf-1
EP0442724A2 (fr) * 1990-02-13 1991-08-21 Kirin-Amgen, Inc. IL-6 humaine modifiée
WO1993012220A1 (fr) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. ANTICORPS DE RECOMBINAISON ET CHIMERIQUES CONTRE c-erbB-2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 103, no. 11, 16 September 1985, Columbus, Ohio, US; abstract no. 84021 *
VERONESE F. ET AL.: "SURFACE MOFIFICATION OF PROTEINS. ACTIVATION OF MONOMETHOXY-POLYETHYLENE GLYCOLS BY PHENYLCHLOROFORMATES AND MODIFICATION OF RIBONUCLEASE AND SUPEROXIDE DISMUTASE.", APPL. BIOCHEM. BIOTECHNOL., vol. 11, no. 2, 1985, pages 141 - 152 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
WO1994005332A2 (fr) 1994-03-17
AU5098193A (en) 1994-03-29

Similar Documents

Publication Publication Date Title
WO1994005332A3 (fr) Glycolation de macromolecules glycosylees
EP1656952A3 (fr) Polymères conjugués de l' interferon beta-1A et leurs utilisations
AU4488593A (en) Low diol polyalkylene oxide biologically active proteinaceous substances
CA2069244A1 (fr) Liposome lie a une proteine et contenant un medicament
AU6916996A (en) Polyalkylene ethers as plasticizers and flow aids in poly(1,4-cyclohexanedimethylene terephthalate) resins
NZ336961A (en) Polymer blend comprising a polyester, a polyfunctional acid anhydride and a polyhydric alcohol
AU6020494A (en) Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
AU2755688A (en) Aqueous dispersion of particulate water soluble polymers in polyethylene glycol
AU4250897A (en) Balloon catheters having ultrasonically driven interface surfaces and methods for their use
AU4649189A (en) Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
EP0377567A4 (en) The development of entropic motive force in protein systems and molecular machines using the same
AU4660789A (en) Polypeptide derivatives
ZA865667B (en) Water-based functional fluid thickening combinations or surfactants and hydrocarbyl-substituted acid and/or anhydride/amine terminated poly(oxyalkylene)reaction products
MX198419B (es) Catalizador de oxido de alquileno y proceso.
AU8314387A (en) High molecular compound comprising unit of asialoglycoprotein acceptor-directing compound and unit of chelate-forming compound chemically bonded thereto, and its utilization
CA2025177A1 (fr) Element abrasif
EP0602845A3 (en) Message dispatching in an event driven architecture.
EP0648242A1 (fr) POLYMERISATION DE LA LIGNINE A UN pH ALCALIN.
EP0380750A3 (fr) Polymère de glycidylazide et procédé de préparation
AU1514492A (en) Alkaline protease and microorganism producing the same
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
AU8438998A (en) Glycidyl ether aliphatic polyalcohols as coupling agents in anionic polymerization
AU7635887A (en) Recombinant HTLV-III proteins and uses thereof
AU5444494A (en) 1.8''pcmcia compatible drive having two or more disks
ITRM930157A0 (it) Diaframma per modulo di innesto e suo modulo di innesto, in particolare per autoveicoli.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA